Clinical TrialsFocus remains on lead program ATR-12 in Netherton syndrome, which dosed the first patient in its P1b study, with initial data expected soon.

Regulatory ApprovalsATR-04 has fast track designation, indicating a streamlined development process to potentially bring the therapy to market sooner.

Bears Say

Financial PerformanceFactoring in dilution associated with the two recent financings lowers the 12-month price target to $2.00, from $3.00.

Azitra Inc News

Azitra Stock (AZTR) Rockets on Clinical Trial Update

Azitra stock rallied on Wednesday alongside a clinical trial update. ...

10d ago

AZTR

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Investors seeking all of the latest stock market news for Wednesday will find it in in the TipRanks daily wrap-up. ...

10d ago

AHL

Azitra doses first patient in Phase 1/2 clinical trial of ATR04-484

Azitra (AZTR) announced the dosing of the first patient in its Phase 1/2 clinical trial of ATR04-484, a...

11d ago

AZTR

Upcoming Stock Splits This Week (August 18 to August 22) – Stay Invested

These are the upcoming stock splits for the week of August 18 to August 22, based on TipRanks’ Stock...

21d ago

AZTR

CHSN

Azitra authorizes reverse 1-for-6.66 stock split

Azitra (AZTR) intends to effect a reverse stock split of its common stock at a ratio of 1...

26d ago

AZTR

Azitra Inc.’s ATR04-484 Study: A Promising Step in Treating EGFRi-Associated Rash

Azitra Inc (($AZTR)) announced an update on their ongoing clinical study. Azitra Inc. is conducting a study titled...

2d ago

AZTR

Azitra Inc Modifies Agreement with Alumni Capital

Azitra Inc ( ($AZTR) ) has provided an announcement. On August 26, 2025, Azitra, Inc. entered into a...

8d ago

AZTR

Azitra Inc Announces Reverse Stock Split Implementation

Azitra Inc ( ($AZTR) ) has issued an announcement. On August 20, 2025, Azitra, Inc. filed a certificate...

17d ago

AZTR

Azitra files to sell 2.25M shares of common stock for holders

The company is not selling any securities under this prospectus and will not receive any of the proceeds...

2M ago

AZTR

Azitra Inc Approves Increase in Common Stock Shares

An update from Azitra Inc ( ($AZTR) ) is now available. On July 3, 2025, Azitra, Inc. held...

2M ago

AZTR

Azitra Inc Approves Director Elections and Share Issuance

Azitra Inc ( ($AZTR) ) has shared an announcement. On June 23, 2025, Azitra, Inc. held its annual...

3M ago

AZTR

Azitra Inc Plans Stock Increase at Annual Meeting

The latest announcement is out from Azitra Inc ( ($AZTR) ). Azitra, Inc. announced updates to its 2025...

3M ago

AZTR

Azitra Inc Announces Positive Phase 1b Trial Results

Azitra Inc ( ($AZTR) ) has shared an update. On June 17, 2025, Azitra, Inc. announced promising safety...

3M ago

AZTR

Azitra’s ATR12-351 shows safety in Phase 1b Netherton syndrome trial

Azitra (AZTR) announced “encouraging” safety data from the initial clinical trial of its live biotherapeutic candidate, ATR12-351, targeting...

3M ago

AZTR

AZTR FAQ

What was Azitra Inc’s price range in the past 12 months?

Azitra Inc lowest stock price was $0.70 and its highest was $4.44 in the past 12 months.

What is Azitra Inc’s market cap?

Azitra Inc’s market cap is $4.76M.

When is Azitra Inc’s upcoming earnings report date?

Azitra Inc’s upcoming earnings report date is Nov 18, 2025 which is in 72 days.

How were Azitra Inc’s earnings last quarter?

Azitra Inc released its earnings results on Aug 11, 2025. The company reported -$1.199 earnings per share for the quarter, beating the consensus estimate of -$1.399 by $0.2.

Is Azitra Inc overvalued?

According to Wall Street analysts Azitra Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Azitra Inc pay dividends?

Azitra Inc does not currently pay dividends.

What is Azitra Inc’s EPS estimate?

Azitra Inc’s EPS estimate is -1.4.

How many shares outstanding does Azitra Inc have?

Azitra Inc has 5,404,968 shares outstanding.

What happened to Azitra Inc’s price movement after its last earnings report?

Azitra Inc reported an EPS of -$1.199 in its last earnings report, beating expectations of -$1.399. Following the earnings report the stock price went down -7.547%.

Which hedge fund is a major shareholder of Azitra Inc?

Currently, no hedge funds are holding shares in AZTR

Company Description

Azitra Inc

Azitra Inc (AZTR) is a biotechnology company that operates in the healthcare sector. The company is focused on developing innovative therapies for dermatological conditions by leveraging its proprietary microbiome technology platform. Azitra's core products aim to address a range of skin diseases and conditions by harnessing the natural properties of beneficial bacteria.